Region Oestergoetland
- Address
- lock Available on a paid plan
Region Oestergoetland Clinical Research Center
Region Oestergoetland is a comprehensive clinical research center conducting multi-specialty trials across a diverse range of therapeutic areas. The center demonstrates particular strength in oncology research, with extensive experience in both solid tumors and hematologic malignancies, as well as significant expertise in metabolic disorders, inflammatory conditions, and infectious diseases.
- Oncology: Studies in acute myeloid leukemia, lung cancer, colorectal cancer, vulvar cancer, melanoma, multiple myeloma, pancreatic cancer, and various lymphomas including Hodgkin lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia
- Metabolic and Endocrine Disorders: Research in diabetes (Type 1 and Type 2), including innovative trials evaluating SGLT2 inhibitors, immunotherapies for diabetes prevention, and metabolic optimization strategies
- Nephrology and Immunology: Specialized studies in IgA nephropathy, C3 glomerulopathy, chronic kidney disease with hypertension, and complement-mediated renal diseases
- Inflammatory and Gastrointestinal Diseases: Trials in Crohn's disease, ulcerative colitis, and other inflammatory bowel conditions, including novel biologic therapies and treatment optimization studies
The center excels in conducting sophisticated pediatric oncology trials through collaborative networks, implements precision medicine approaches including genomic biomarker-guided therapies, and conducts innovative addiction medicine research. Additional research focuses include respiratory diseases (asthma, COPD, tuberculosis), surgical optimization, obstetric care, cardiovascular conditions, dermatology (atopic dermatitis, allergic rhinoconjunctivitis), and behavioral neuroscience studies. The facility's participation in international multicenter trials demonstrates its commitment to advancing evidence-based medicine across multiple disciplines.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 62 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 62 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Karolinska University Hospital2active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Karolinska University Hospital4trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Region Oestergoetland
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects with TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy | Kartos Therapeutics Inc. | Phase IV | Not Recruiting | Aug 2023 | Jul 2024 |
IMP list
lock Showing 1 of 62 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 4 | Unknown | 2017-03-07 | 2024-04-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.